James W Antoon

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/10895162/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Severe cutaneous adverse reactions: comparing outcomes in children with and without complex chronic conditions. Journal of Allergy and Clinical Immunology: in Practice, 2020, 8, 790-792.e3.	3.8	0
2	A Retrospective Cohort Study of the Management and Outcomes of Children Hospitalized with Stevens-Johnson Syndrome or Toxic Epidermal Necrolysis. Journal of Allergy and Clinical Immunology: in Practice, 2019, 7, 244-250.e1.	3.8	19
3	Incidence, outcomes, and resource use in children with Stevensâ€Johnson syndrome and toxic epidermal necrolysis. Pediatric Dermatology, 2018, 35, 182-187.	0.9	40
4	Clinical approach to endogenous lipoid pneumonia. Clinical Respiratory Journal, 2016, 10, 259-263.	1.6	13
5	Pediatric Fever of Unknown Origin. Pediatrics in Review, 2015, 36, 380-391.	0.4	14
6	Preferential star strand biogenesis of preâ€miRâ€24â€2 targets PKCâ€alpha and suppresses cell survival in MCFâ€7 breast cancer cells. Molecular Carcinogenesis, 2014, 53, 38-48.	2.7	45
7	Inhibition of sphingosine kinase-2 ablates androgen resistant prostate cancer proliferation and survival. Pharmacological Reports, 2014, 66, 174-178.	3.3	24
8	3-Ketone-4,6-diene ceramide analogs exclusively induce apoptosis in chemo-resistant cancer cells. Bioorganic and Medicinal Chemistry, 2014, 22, 1412-1420.	3.0	13
9	Fever of Unknown Origin in a Child. Clinical Pediatrics, 2013, 52, 99-102.	0.8	6
10	Inhibition of p38 mitogen-activated protein kinase alters microRNA expression and reverses epithelial-to-mesenchymal transition. International Journal of Oncology, 2013, 42, 1139-1150.	3.3	32
11	MEK5/ERK5 Signaling Suppresses Estrogen Receptor Expression and Promotes Hormone-Independent Tumorigenesis. PLoS ONE, 2013, 8, e69291.	2.5	50
12	Migratory Polyarthritis in a Child. Clinical Pediatrics, 2012, 51, 401-403.	0.8	0
13	Sphingosine kinase isoforms as a therapeutic target in endocrine therapy resistant luminal and basal-A breast cancer. Experimental Biology and Medicine, 2012, 237, 832-844.	2.4	25
14	Inhibition of p38-MAPK alters SRC coactivation and estrogen receptor phosphorylation. Cancer Biology and Therapy, 2012, 13, 1026-1033.	3.4	26
15	Neurocognitive Effects of Chemotherapy and Endocrine Therapies in the Treatment of Breast Cancer: Recent Perspectives. Cancer Investigation, 2012, 30, 135-148.	1.3	33
16	Altered Death Receptor Signaling Promotes Epithelial-to-Mesenchymal Transition and Acquired Chemoresistance. Scientific Reports, 2012, 2, 539.	3.3	32
17	Incomplete Reporting in a Case Report of Corticosteroids in the Treatment of Alcohol-Induced Rhabdomyolysis. Mayo Clinic Proceedings, 2012, 87, 803.	3.0	1
18	Diagnostic Approach to Fever of Unknown Origin. Clinical Pediatrics, 2012, 51, 1091-1094.	0.8	7

#	Article	IF	CITATIONS
19	Antiestrogenic activity of flavonoid phytochemicals mediated via the c-Jun N-terminal protein kinase pathway. Cell-type specific regulation of estrogen receptor alpha. Journal of Steroid Biochemistry and Molecular Biology, 2012, 132, 186-193.	2.5	22
20	Dual inhibition of sphingosine kinase isoforms ablates TNF-induced drug resistance. Oncology Reports, 2012, 27, 1779-86.	2.6	20
21	An unusual case of pediatric shortness of breath—questions. Pediatric Nephrology, 2012, 27, 921-922.	1.7	2
22	An unusual case of pediatric shortness of breath—answers. Pediatric Nephrology, 2012, 27, 923-925.	1.7	3
23	Anti-proliferative effects of the novel ceramide analog (S)-2-(benzylideneamino)-3-hydroxy-N-tetrade-cylpropanamide in chemoresistant cancer. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 2624-2628.	2.2	12
24	Pharmacology and anti-tumor activity of RWJ67657, a novel inhibitor of p38 mitogen activated protein kinase. American Journal of Cancer Research, 2012, 2, 446-58.	1.4	13
25	Corticosteroids in the Treatment of Alcohol-Induced Rhabdomyolysis. Mayo Clinic Proceedings, 2011, 86, 1005-1007.	3.0	27
26	Targeting NFÄß mediated breast cancer chemoresistance through selective inhibition of sphingosine kinase-2. Cancer Biology and Therapy, 2011, 11, 678-689.	3.4	135
27	Sphingosine kinase: A promising cancer therapeutic target. Cancer Biology and Therapy, 2011, 11, 647-650.	3.4	16
28	Pharmacological inhibition of sphingosine kinase isoforms alters estrogen receptor signaling in human breast cancer. Journal of Molecular Endocrinology, 2011, 46, 205-216.	2.5	47
29	Novel d-erythro N-octanoyl sphingosine analogs as chemo- and endocrine-resistant breast cancer therapeutics. Cancer Chemotherapy and Pharmacology, 2010, 65, 1191-1195.	2.3	26
30	Adult human mesenchymal stem cells enhance breast tumorigenesis and promote hormone independence. Breast Cancer Research and Treatment, 2010, 121, 293-300.	2.5	101
31	Novel anti-viability ceramide analogs: Design, synthesis, and structure–activity relationship studies of substituted (S)-2-(benzylideneamino)-3-hydroxy-N-tetradecylpropanamides. Bioorganic and Medicinal Chemistry, 2010, 18, 5316-5322.	3.0	15
32	Antiestrogenic Effects of the Novel Sphingosine Kinase-2 Inhibitor ABC294640. Endocrinology, 2010, 151, 5124-5135.	2.8	105
33	Effects of human mesenchymal stem cells on ER-positive human breast carcinoma cells mediated through ER-SDF-1/CXCR4 crosstalk. Molecular Cancer, 2010, 9, 295.	19.2	89
34	Sphingolipids as Determinants of Apoptosis and Chemoresistance in the MCF-7 Cell Model System. Experimental Biology and Medicine, 2009, 234, 1253-1263.	2.4	21
35	Design, Synthesis, and Biological Activity of a Family of Novel Ceramide Analogues in Chemoresistant Breast Cancer Cells. Journal of Medicinal Chemistry, 2009, 52, 5748-5752.	6.4	37
36	Synthesis of 2,2′â€bipyridylâ€type compounds via the suzukiâ€miyaura crossâ€coupling reaction. Journal of Heterocyclic Chemistry, 2007, 44, 363-367.	2.6	31